Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 8:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 3,990 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Small-Cell Lung Cancer (SCLC) Clear all
Terminated Phase 2 Interventional Results available

Radiation Therapy or Observation After Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

NCT00776100
View directory record Official record
Conditions
Lung Cancer
Interventions
clinical observation, radiation therapy
Other · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 120 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
168
States / cities
Scottsdale, Arizona • Hartford, Connecticut • Jacksonville, Florida + 103 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 16, 2026, 8:18 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

NCT04380636
View directory record Official record
Conditions
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
Interventions
Pembrolizumab, Olaparib, Placebo for olaparib, Etoposide, Carboplatin, Cisplatin, Paclitaxel, Pemetrexed, Thoracic Radiotherapy, Durvalumab
Biological · Drug · Radiation
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
33
States / cities
Mobile, Alabama • Jonesboro, Arkansas • Fullerton, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 16, 2026, 8:18 AM EDT
Completed Phase 3 Interventional

A Randomized Phase 3 Trial of Pemetrexed and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

NCT00087711
View directory record Official record
Conditions
Non Small Cell Lung Carcinoma
Interventions
pemetrexed, gemcitabine, cisplatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,713 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
18
States / cities
Sacramento, California • Torrance, California • Jacksonville, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Oct 16, 2026, 8:18 AM EDT
Completed Not applicable Interventional

Integrated Versus Standard Palliative Care in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

NCT01038271
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Standard Palliative Care Group, Integrated Palliative Care Intervention
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Oct 16, 2026, 8:18 AM EDT
Withdrawn Phase 2 Interventional

INNO-206 in Patients With Small Cell Lung Cancer (SCLC)

NCT00472771
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
INNO-206
Drug
Lead sponsor
CytRx
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
7
States / cities
Chicago, Illinois • Billings, Montana • Albany, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2012 · Synced Oct 16, 2026, 8:18 AM EDT
Completed Phase 2 Interventional

Fenretinide in Treating Patients With Recurrent Small Cell Lung Cancer

NCT00009971
View directory record Official record
Conditions
Lung Cancer
Interventions
fenretinide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
Ann Arbor, Michigan • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 16, 2026, 8:18 AM EDT
Active, not recruiting Phase 3 Interventional

Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer

NCT06732401
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Ceralasertib, Computed Tomography, Durvalumab, Echocardiography Test
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
192
States / cities
Jonesboro, Arkansas • Beverly Hills, California • Los Angeles, California + 163 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 16, 2026, 8:18 AM EDT
Completed Phase 3 Interventional Results available

Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC

NCT00806819
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Nintedanib (BIBF1120), Pemetrexed, B12, dexamethasone (or corticosteroid equivalent), placebo, Folic Acid
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
718 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
40
States / cities
Downy, California • Fountain Valley, California • Fullerton, California + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Oct 16, 2026, 8:18 AM EDT
Completed Phase 3 Interventional

Marimastat in Treating Patients With Stage III Non-small Cell Lung Cancer

NCT00002911
View directory record Official record
Conditions
Lung Cancer
Interventions
marimastat
Drug
Lead sponsor
ILEX Oncology Services, Incorporated
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2004
U.S. locations
48
States / cities
Huntsville, Alabama • Phoenix, Arizona • Greenbrae, California + 38 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 16, 2026, 8:18 AM EDT
Completed Phase 1 Interventional

A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer

NCT01300533
View directory record Official record
Conditions
Metastatic Cancer, Cancer, Solid Tumors
Interventions
BIND-014
Drug
Lead sponsor
BIND Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
6
States / cities
Scottsdale, Arizona • Greenbrae, California • Los Angeles, California + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2016 · Synced Oct 16, 2026, 8:18 AM EDT
Terminated Phase 2 Interventional Results available

A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC

NCT02387216
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, NSCLC, Adenocarcinoma, Heregulin
Interventions
MM-121, Docetaxel
Drug
Lead sponsor
Elevation Oncology
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
17
States / cities
Tucson, Arizona • Los Angeles, California • Santa Rosa, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 16, 2026, 8:18 AM EDT
Completed Phase 2 Interventional Results available

AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer

NCT00410904
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer
Interventions
cediranib maleate, pemetrexed disodium
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
2
States / cities
Baltimore, Maryland • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 13, 2018 · Synced Oct 16, 2026, 8:18 AM EDT
Active, not recruiting Not applicable Interventional

Online Psychosocial Intervention in Improving Social Well-Being and Support in Women With Stage I-IV Non-small Cell Lung Cancer Undergoing Treatment

NCT03731585
View directory record Official record
Conditions
Non-Small Cell Lung Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Behavioral Intervention, Educational Intervention, Questionnaire Administration, Support Group Therapy
Behavioral · Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 16, 2026, 8:18 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer

NCT03559049
View directory record Official record
Conditions
Stage IV Non-small Cell Lung Cancer
Interventions
Pembrolizumab, Pemetrexed, Carboplatin, Rucaparib
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
3
States / cities
Ann Arbor, Michigan • St Louis, Missouri • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 16, 2026, 8:18 AM EDT
Terminated Phase 3 Interventional Results available

Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer

NCT00673049
View directory record Official record
Conditions
Carcinoma, Large Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Adenosquamous Cell
Interventions
CP 751,871 (Figitumumab), Erlotinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
583 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
69
States / cities
Fort Smith, Arkansas • Hot Springs, Arkansas • Lakeport, California + 53 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2013 · Synced Oct 16, 2026, 8:18 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer

NCT07285148
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, EGFR Mutation, Metastatic Lung Cancer, MET Alteration
Interventions
ANS014004 + PLB1004, ANS014004 + Osimertinib
Drug
Lead sponsor
Beijing Pearl Biotechnology Limited Liability Company
Industry
Eligibility
18 Years and older
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 16, 2026, 8:18 AM EDT
Completed Phase 1 Interventional

Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer

NCT00712504
View directory record Official record
Conditions
Advanced Solid Tumors, Non Small Cell Lung Cancer
Interventions
sunitinib, docetaxel
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
5
States / cities
Birmingham, Alabama • Nashville, Tennessee • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 11, 2008 · Synced Oct 16, 2026, 8:18 AM EDT
Not listed Phase 1Phase 2 Interventional

Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy

NCT02446704
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Olaparib, Temozolomide
Drug
Lead sponsor
Zofia Piotrowska
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Oct 16, 2026, 8:18 AM EDT
Active, not recruiting Phase 1 Interventional

Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer

NCT04837716
View directory record Official record
Conditions
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Bevacizumab, Carboplatin, Ensartinib, Pemetrexed
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 16, 2026, 8:18 AM EDT
Completed Phase 1 Interventional

GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients

NCT02575404
View directory record Official record
Conditions
Melanoma, Non-Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
Interventions
GR-MD-02, Pembrolizumab
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 16, 2026, 8:18 AM EDT
Withdrawn No phase listed Observational

Optical Coherence Tomography of the Airway for Lung Cancer or Lung Disease

NCT00733252
View directory record Official record
Conditions
Lung Cancer, Malignant Mesothelioma, Metastatic Cancer, Nonmalignant Neoplasm, Precancerous Condition
Interventions
bronchoscopic and lung imaging studies, diagnostic bronchoscopy, histopathologic examination, optical coherence tomography
Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 2, 2015 · Synced Oct 16, 2026, 8:18 AM EDT
Terminated Phase 2 Interventional

Cisplatin/Irinotecan With Concurrent Radiation for Inoperable NSCLC

NCT02275806
View directory record Official record
Conditions
Lung Neoplasms, Non-Small Cell Lung Cancer
Interventions
Irinotecan, Cisplatin
Drug
Lead sponsor
Leo W. Jenkins Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Oct 16, 2026, 8:18 AM EDT
Completed No phase listed Observational

Oncology Research Information Exchange Network (ORIEN) Lung Cancer Study

NCT02803333
View directory record Official record
Conditions
Lung Cancer, Non-small Cell Lung Cancer
Interventions
No Intervention
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Oct 16, 2026, 8:18 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

NCT02817633
View directory record Official record
Conditions
Neoplasms
Interventions
TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older
Enrollment
463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
64
States / cities
Goodyear, Arizona • Scottsdale, Arizona • Tucson, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 16, 2026, 8:18 AM EDT